Zocere, Inc. Expands Development Portfolio, Licenses Neuroprotectant Technology For Stroke And Other Brain Trauma From STC.UNM
3/10/2014 8:51:05 AM
ALBUQUERQUE, N.M.--(BUSINESS WIRE)--Zocere, Inc., has signed a licensing agreement for a novel neuroprotectant treatment for ischemic stroke and other neurological disorders from STC.UNM, the University of New Mexico’s technology transfer and economic development organization. Zocere is a New Mexico-based pharmaceutical company developing drug-based treatments for neurological diseases, with the most compelling data to date for the treatment of stroke. Currently, there are few treatment options for blood clot-induced ischemic stroke, which accounts for 87 percent of strokes. Those on the market are little used and have risks associated with their use. Zocere’s newly licensed STEP protein, a biologic that is a cell-permeable, recombinant peptide, shows promise as a potent “brain saving” drug when administered post stroke.
Help employers find you! Check out all the jobs and post your resume.
comments powered by